Life Science Intelligence

Apreo Health is taking on one of respiratory medicine’s most persistent challenges with an approach built around a deceptively simple idea: instead of destroying diseased lung tissue, work with the lung to help it breathe. Under the leadership of Co-Founder and CEO Karun Naga, the company has advanced its investigational BREATHE Airway Scaffold from an early concept to a 200-patient pivotal trial, backed by a $130 million Series B and a team determined to establish a new treatment option for people living with severe emphysema. For Naga, however, Apreo is about more than building another medical device company. It is the culmination of decades of lessons about pioneering innovation, intellectual property, people, failure, persistence, and the responsibility that comes with trying to do something medicine has not been able to do before. From Patent Attorney to Entrepreneur Karun Naga has spent much of his career around people trying to create things that do not yet exist. An engineer b...

Tulyp Medical is developing a pressure-guided limb-perfusion system designed to prevent procedure-associated acute limb ischemia by enabling clinicians to continuously monitor and regulate blood delivery to the affected limb. Initially focused on patients undergoing procedures involving femoral arterial access, including venoarterial extracorporeal membrane oxygenation (VA-ECMO) and other forms of mechanical circulatory support, Tulyp is seeking to shift limb perfusion from a passive, reactive practice to an actively managed therapy. Origin Story Tulyp Medical began with a problem its founders, a group of clinicians and cardiovascular-device experts, repeatedly encountered in practice. Femoral access devices introduced through the femoral artery can compromise blood flow to the lower limb, yet clinicians may not recognize inadequate perfusion until injury has already begun. The founding premise was straightforward: rather than waiting for signs of a complication, clinicians should be ...

Under the direction of Co-Founder and CEO Oliver Piepenstock, Noah Labs is developing a new approach to heart failure monitoring built around an unlikely source of clinical information: the human voice. The Boston- and Berlin-based company has developed Vox, an investigational AI-driven software medical device designed to detect vocal changes associated with worsening heart failure before hospitalization. Its deep learning models are trained on more than three million voice samples, while its commercially deployed Ark remote patient monitoring platform provides a foundation in clinical workflows and data. With Vox now advancing through a pivotal U.S. trial following FDA Breakthrough Device Designation, Noah Labs is working toward a larger vision Piepenstock describes as “the world’s first voice-powered operating system for heart failure care.” Origin Story Noah Labs began in Berlin in late 2021, when Piepenstock met Co-Founder and CTO Marcus Hott through Entrepreneur First. Their backg...

Under the direction of President and CEO Christopher Gleason, Moximed is advancing a joint-preserving approach to knee osteoarthritis with the MISHA Knee System, an implantable shock absorber designed to unload the medial compartment of the knee without replacing the joint. Built on nearly two decades of clinical development and more than a decade of technology refinement, MISHA is intended to address a substantial gap between conservative care and knee arthroplasty. Now commercially available in the U.S., Moximed is focused on scaling adoption, expanding its body of clinical evidence, and establishing joint unloading as a new treatment paradigm for patients who have exhausted non-surgical options but are unwilling to undergo or are not indicated for knee replacement. Origin Story Moximed was co-founded by Anton Clifford, PhD, and LSI Alumni Josh Makower, MD, around a straightforward biomechanical premise: reducing the forces acting across an osteoarthritic knee could address an import...

Under the direction of Sonia Martínez Arca, PhD, Batea Oncology is developing what it describes as the first mechanomedicine platform for cancer, beginning with glioblastoma, one of oncology’s deadliest and most treatment-resistant diseases. Rather than relying on traditional pharmacological approaches, the company’s implantable medical device leverages the mechanical behavior of cancer cells to capture them after surgery and improve their response to radiotherapy. As Batea Oncology prepares to begin its first-in-human clinical trial, the company is working to establish an entirely new therapeutic paradigm for solid tumors with high recurrence rates. Origin Story Batea Oncology was founded with a straightforward goal: translate promising laboratory discoveries into therapies capable of improving outcomes for patients facing some of oncology’s greatest unmet needs. “Our motivation to create Batea Oncology was to translate the very promising results obtained in the lab to the patients in...

On July 27, American Industrial Partners completed its $1.27 billion acquisition of Avanos Medical, taking the pain management and specialty nutrition company private. Two days later, MIMEDX announced an agreement to acquire Sanara MedTech for approximately $350 million, combining two public wound care businesses. One was a private equity buyout. The other was consolidation between two smaller public companies. Together, they point to another development in medtech M&A: remaining independent may be getting harder to justify for companies caught between startup scale and large-cap status. Medtech M&A Activity Is Adding Up In May, we described the medtech M&A environment as active but not yet a boom. Since then, the pace tracked by Compass AI suggests more of the conditions for an acceleration are falling into place. Between May 1 and July 30, Compass AI recorded 13 medtech M&A transactions. Among the disclosed deals were Roche’s $1.05 billion acquisition of PathAI, Med...